Choosing important health outcomes for comparative effectiveness research: 6th annual update to a systematic review of core outcome sets for research.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 26 07 2020
accepted: 17 12 2020
entrez: 12 1 2021
pubmed: 13 1 2021
medline: 8 5 2021
Statut: epublish

Résumé

An annual update to a systematic review of core outcome sets (COS) for research ensures that the COMET database is up-to-date. The aims of this study were to: (i) identify COS that were published or indexed in 2019 and to describe the methodological approaches used in these studies; (ii) investigate whether children have been included as participants in published COS development studies, and which methods have been used to facilitate their participation; iii) update a previous exercise to identify COS relevant to the most burdensome global diseases and injuries. MEDLINE and SCOPUS were searched to identify studies published or indexed between (and inclusive of) January 2019 and December 2019. Automated screening methods were used to rank the citations in order of relevance; the top 25% in ranked priority order were screened for eligibility. COS were assessed against each of the Core Outcome Set-STAndards for Development (COS-STAD). A search of the COMET database was undertaken to identify COS relevant to the 25 leading causes of disease burden. Thirty-three studies, describing the development of 37 COS, were included in this update. These studies have been added to the COMET database, which now contains 370 published (1981-2019) COS studies for clinical research. Six (18%) of the 33 studies in this update were deemed to have met all of the minimum standards for COS development (range = 4 to 12 criteria, median = 9 criteria). Of the 370 COS studies published to date, 82 COS have been developed for paediatric health conditions and children would have been eligible to participate in 68/82 of these studies. Eleven of these 68 (16%) COS studies have included children as participants within the development process, most commonly through participation in Delphi surveys. Relevant COS were identified for 22/25 leading causes of global disease burden. There has been a demonstrated increase in COS developed for both research and routine practice, and consistently high inclusion of patient participants. COS developed for paediatric conditions need to further incorporate the perspectives of children, alongside parents and other adults, and adopt research methods fit for this purpose. COS developers should consider the gaps identified in this update as priorities for COS development.

Sections du résumé

BACKGROUND
An annual update to a systematic review of core outcome sets (COS) for research ensures that the COMET database is up-to-date. The aims of this study were to: (i) identify COS that were published or indexed in 2019 and to describe the methodological approaches used in these studies; (ii) investigate whether children have been included as participants in published COS development studies, and which methods have been used to facilitate their participation; iii) update a previous exercise to identify COS relevant to the most burdensome global diseases and injuries.
METHODS
MEDLINE and SCOPUS were searched to identify studies published or indexed between (and inclusive of) January 2019 and December 2019. Automated screening methods were used to rank the citations in order of relevance; the top 25% in ranked priority order were screened for eligibility. COS were assessed against each of the Core Outcome Set-STAndards for Development (COS-STAD). A search of the COMET database was undertaken to identify COS relevant to the 25 leading causes of disease burden.
RESULTS
Thirty-three studies, describing the development of 37 COS, were included in this update. These studies have been added to the COMET database, which now contains 370 published (1981-2019) COS studies for clinical research. Six (18%) of the 33 studies in this update were deemed to have met all of the minimum standards for COS development (range = 4 to 12 criteria, median = 9 criteria). Of the 370 COS studies published to date, 82 COS have been developed for paediatric health conditions and children would have been eligible to participate in 68/82 of these studies. Eleven of these 68 (16%) COS studies have included children as participants within the development process, most commonly through participation in Delphi surveys. Relevant COS were identified for 22/25 leading causes of global disease burden.
CONCLUSION
There has been a demonstrated increase in COS developed for both research and routine practice, and consistently high inclusion of patient participants. COS developed for paediatric conditions need to further incorporate the perspectives of children, alongside parents and other adults, and adopt research methods fit for this purpose. COS developers should consider the gaps identified in this update as priorities for COS development.

Identifiants

pubmed: 33434219
doi: 10.1371/journal.pone.0244878
pii: PONE-D-20-21185
pmc: PMC7802923
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0244878

Subventions

Organisme : Department of Health
ID : NF-SI_0513-10025
Pays : United Kingdom

Déclaration de conflit d'intérêts

EG and PRW are members of the COMET Management Group. SLG and KMS have declared that no competing interests exist. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Références

Br J Surg. 2020 Jul;107(8):1013-1022
pubmed: 32181505
PLoS One. 2015 Jun 26;10(6):e0129514
pubmed: 26115172
Res Involv Engagem. 2020 May 6;6:19
pubmed: 32391170
PLoS One. 2018 Dec 28;13(12):e0209869
pubmed: 30592741
Trials. 2020 Jun 25;21(1):570
pubmed: 32586349
BMJ Open. 2020 Sep 6;10(9):e036562
pubmed: 32895272
PLoS Med. 2016 Oct 18;13(10):e1002148
pubmed: 27755541
PLoS One. 2019 Dec 12;14(12):e0225980
pubmed: 31830081
PLoS One. 2014 Jun 16;9(6):e99111
pubmed: 24932522
Trials. 2017 Jun 20;18(Suppl 3):280
pubmed: 28681707
PLoS One. 2016 Dec 14;11(12):e0168403
pubmed: 27973622
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326
J Clin Epidemiol. 2020 Sep;125:206-212.e1
pubmed: 31945480
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
PLoS Med. 2017 Nov 16;14(11):e1002447
pubmed: 29145404
Database (Oxford). 2019 Jan 1;2019:
pubmed: 31697361
PLoS One. 2018 Feb 13;13(2):e0190695
pubmed: 29438429
PLoS One. 2016 Jan 19;11(1):e0146444
pubmed: 26785121
JAMA Pediatr. 2016 Mar;170(3):205-11
pubmed: 26619178

Auteurs

Elizabeth Gargon (E)

Department of Health Data Science, University of Liverpool, Liverpool, United Kingdom.

Sarah L Gorst (SL)

Department of Health Data Science, University of Liverpool, Liverpool, United Kingdom.

Karen Matvienko-Sikar (K)

School of Public Health, University College Cork, Cork, Ireland.

Paula R Williamson (PR)

Department of Health Data Science, University of Liverpool, Liverpool, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH